Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12843981 | 0.83 | CNR1 (0.53) | NAMPTHDAC6CNR1KMT2AMEN1 | |
| SCHEMBL12775199 | 0.80 | NAMPT (0.50) | NAMPTHDAC6CNR1KMT2AMEN1 | |
| SCHEMBL12775509 | 0.80 | NAMPT (0.53) | NAMPTHDAC6CNR1KMT2AMEN1 | |
| SCHEMBL12844125 | 0.78 | ACKR3 (0.59) | — | |
| SCHEMBL12844126 | 0.78 | CNR1 (0.40) | HDAC6CNR1 | |
| SCHEMBL28111734 | 0.74 | NAMPT (0.49) | NAMPTHDAC6 | |
| SCHEMBL12844495 | 0.73 | PLK1 (0.43) | HDAC6 | |
| SCHEMBL938902 | 0.73 | NAMPT (0.47) | NAMPTHDAC6CNR1TDP1 | |
| SCHEMBL12017925 | 0.72 | NAMPT (0.45) | NAMPTHDAC6CNR1 | |
| SCHEMBL12844003 | 0.72 | CHRM2 (0.40) | CNR1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | NAMPT 2/4885HDAC6 169/4885CNR1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.